Blockchain Registration Transaction Record

Tonix Enrolls First Patient in MDD Phase 2 Trial of TNX-102 SL

Tonix Pharmaceuticals enrolls first patient in HORIZON Phase 2 trial evaluating TNX-102 SL 5.6 mg as first-line MDD monotherapy. Study targets sleep quality, depression severity. TNX-102 SL already FDA-approved for fibromyalgia as TONMYA.

This trial matters because major depressive disorder affects over 280 million people globally, and current treatments often fall short. If TNX-102 SL succeeds, it could offer a new first-line monotherapy that addresses sleep disturbances, a key driver of depression, potentially improving outcomes for millions. The drug's existing FDA approval for fibromyalgia also de-risks its development, making this a pivotal moment for both patients and investors.